Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Alnylam (ALNY) upgraded to Overweight from Equal Weight at Morgan Stanley with analyst David Lebowitz saying he expects Onpattro to ultimately exceed the Street's expectations for 2019 given early metrics about the drug's launch. 2. Ctrip (CTRP) upgraded to Overweight from Neutral at JPMorgan, to Overweight from Equal Weight at Morgan Stanley, to Buy from Neutral at Citi, and to Buy from Underperform at CLSA. 3. Ingersoll-Rand (IR) upgraded to Conviction Buy from Buy at Goldman Sachs with analyst Joe Ritchie saying his conviction in Ingersoll-Rand has strengthened in light of a strong order book exiting 2018, improving price/cost, and a conservative guidance range. 4. ImmunoGen (IMGN) upgraded to Equal Weight from Underweight at Morgan Stanley with analyst Matthew Harrison saying while he expects ImmunoGen to be skewed higher in the next few weeks as investors assess the potential to negotiate with the FDA to file based on the FRalpha-high cohort alone, Harrison said he has limited hope for such a filing. 5. Veritiv (VRTV) upgraded to Buy from Neutral at BofA/Merrill with analyst John Babcock saying he expects an inflection in free cash flow and believes 2019 EBITDA and free cash flow guidance are achievable. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.